MediPharm Labs CEO, Warren Everitt with wife Karlya and their young daughter on the site where they plan to build a medicinal cannabis plant.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MediPharm Labs (LABS) has received an importation license for its Australian operator, MediPharm Labs Australia
  • The license will allow the importation of cannabis, cannabinoids and cannabis resin from Canada
  • The imported products will then be refined into tinctures and other product forms in Australia
  • Shares in the company are currently trading at C$2.98, with a market cap of C$389.95 million

MediPharm Labs (LABS) has received a key importation license for its Australian business, MediPharm Labs Australia.

Issued by the Drug Control section of the Australian Department of Health, the license will be used to establish greater cooperation between MediPharm’s Canadian headquarters and Australian operators – a critical step in evolving its international supply chain.

Upon receipt of the necessary permits, the license will allow for the importation of cannabis, cannabinoids and cannabis resin from Canada to Australia, as well as other global exporters, for refinement into tinctures and other product forms.

“Receiving this licence is an important milestone as we continue to build a multi-jurisdictional GMP-certified pharmaceutical- quality platform to serve the world’s most attractive medical cannabis markets”, said Pat McCutcheon, CEO of MediPharm.

“With the initial phases of our Australian facility built-out, we are on track to establishing a global cannabis supply chain leveraging our GMP-certified Canadian facility, technology and access to high quality, fully traceable, cannabis biomass converted to pharma quality concentrates in Canada, to supply MediPharm Labs Australia, its local market, and other permissible global jurisdictions.”

In December 2019, MediPharm received confirmation from the Australian Therapeutic Goods Association that its Canadian manufacturing facility had met the requirements for GMP as a producer of cannabis as a medicine and as an active pharmaceutical ingredient.

While this certification only applies to the Australian market, it adds to a body of evidence that will support MediPharm in qualifying to supply other medical cannabis products around the world.

Shares in the company are currently trading at C$2.98, with a market cap of C$389.95 million.

More From The Market Herald

" The Market Herald’s Weekly Cannabis Report

Weekly Update – Top Cannabis News Stories

" BioHarvest Sciences welcomes Gavriel Lambert to the Board of Advisors

BioHarvest Sciences (BHSC) has appointed Gavriel Lambert to serve on its Board of Advisors.
Pure Extracts Technologies - CEO, Ben Nikolaevsky.

" Pure Extracts (CSE:PULL) signs supplier agreement with Shoppers Drug Mart

Pure Extracts (PULL) has signed a cannabis supplier agreement with Shoppers Drug Mart.

" Tilray (TSX:TLRY) expands medical cannabis products in the UK

Tilray Brands’ (TLRY) medical cannabis division, Tilray Medical, has expanded its medical cannabis offerings in the United Kingdom.